[Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2016 Apr;37(4):334-6. doi: 10.3760/cma.j.issn.0253-2727.2016.04.017.

[Article in Chinese]

Authors

Yingling Zu, Yanli Zhang, Jian Zhou, Huifang Zhao, Ruirui Gui, Zhen Li, Mengjuan Li, Xudong Wei, Yongping Song¹

Affiliation

¹ Department of Hematopathy, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.

PMID: 27093999
PMCID: PMC7343089
DOI: 10.3760/cma.j.issn.0253-2727.2016.04.017

No abstract available

MeSH terms

Aclarubicin / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cytarabine / therapeutic use
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Interferons / therapeutic use*
Interleukin-2 / therapeutic use*
Leukemia, Myeloid, Acute / drug therapy*
Recurrence
Remission Induction
Thalidomide / therapeutic use*

Substances

Interleukin-2
Cytarabine
Granulocyte Colony-Stimulating Factor
Thalidomide
Aclarubicin
Interferons

Supplementary concepts

CAG protocol